No. 1 is SCBGENOME(E) +68.99%
TISCO Global Healthcare RMF
Shows where this fund stands in its group. Not investment advice · Data as of 4 Nov 2026
TGHRMF-B is a fund of funds that puts 98.50% into units of other funds, spread across several funds
This fund's manager selects the funds and adjusts their weights. The funds it holds also charge their own fees
All funds, as disclosed in the AMC fact sheet · The stocks these funds hold are shown below · This fund's performance therefore depends on the funds it holds
Over the past year it was in the top 25% of its group; there is no rank for a longer period yet
No. 1 is SCBGENOME(E) +68.99%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 4 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | MAX |
|---|---|---|---|---|---|---|---|
| +16.89% | +5.12% | +5.83% | +13.40% | +14.69% | +24.28% | +24.45% | +17.80% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun |
|---|
Largest drawdown in the selected period −19.72% Previous peak 2 Sep 2024 (NAV 15.4590) → Trough 7 Aug 2025 (NAV 12.4102) · Back to the previous peak on 19 Aug 2026, after 1 year
Currently 0.00% from the peak NAV of 16.9964 (4 Nov 2026)
Over 1 year, TGHRMF-B returned 1.52 per unit of volatility, ranking 6 of 40 funds · The highest is FP HCARE-A (1.66)
กองทุนจะลงทุนในหรือมีไว้ซึ่งหน่วยลงทุนของกองทุนรวมตราสารทุนต่างประเทศ และ/หรือกองทุนรวมอีทีเอฟตราสารทุนต่างประเทศ ที่มีนโยบายการลงทุนในตราสารทุนของบริษัทที่ดำเนินธุรกิจที่เกี่ยวข้องกับอุตสาหกรรม Healthcare หรือบริษัทที่มีรายได้หลักจากการประกอบกิจการที่เกี่ยวข้องกับอุตสาหกรรม Healthcare… Its largest holdings are ISHARES GLOBAL HEALTHCARE ETF 74.07% · STATE STREET HEALTH CARE SELECT SECTOR SPDR ETF 16.04% · ISHARES BIOTECHNOLOGY ETF 8.39% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 1 Jul 2024, its NAV has fallen as much as −19.72% from its peak.
Actual total expense ratio (TER) 1.20% a year, against a ceiling of 4.82%. Management fee 0.94%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Diabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
An American company selling scientific instruments, reagents and services for laboratories
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Based on each ETF's actual share of the fund's value · Weighted by each fund held × the stocks that fund holds, covering 100% of the money invested in other funds. Uses each fund's top 10, so figures are a minimum · ISHARES GLOBAL HEALTHCARE as of 27 Oct 2026 · State Street Health Care Select Sector SPDR as of 22 Oct 2026 · ISHARES BIOTECHNOLOGY as of 22 Oct 2026 · Illustrations are for explanation only, not individual stock recommendations
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +0.3 | +2.6 | −7.7 | −1.0 | +1.5 | +5.5 | +1.4 | +4.2 | −1.8 | +9.2 | +2.4 | · | +16.9* |
| 2025 | +6.0 | +1.7 | −2.3 | −3.1 | −4.7 | +1.0 | −3.7 | +5.1 | +0.9 | +2.7 | +8.0 | −1.1 | +10.1 |
| 2024 | · | · | · | · | · | · | +2.7 | +4.2 | −3.4 | −4.3 | −0.6 | −6.9 | −8.5* |
Minimum first purchase not set, subsequent purchases not set. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+3
TGHRMF-B is a retirement mutual fund (RMF). You can buy up to 30% of your assessable income, capped at 500,000 THB a year together with other retirement funds. You must hold it for at least 5 years and can sell only once you turn 55. Check the latest conditions with the Revenue Department before investing
Hedged at the manager's discretion. As of 30 Sep 2026, 90.96% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · TGHRMF-B: no dividends, TER 1.20% · TGHRMF-A: no dividends, TER 1.60% · TGHRMF-P: no dividends